Maves’ change of heart on ephedra
This article was originally published in The Tan Sheet
Executive Summary
Letter to FDA signed by former CHPA President and current American Medical Association Exec VP & CEO Michael Maves, MD, reiterates AMA's call for ephedrine alkaloid products to be removed from the market due to the number of related AERs. While Maves was at CHPA, the trade association opposed FDA's reliance on AERs in developing regulatory restrictions for ephedrine alkaloid products. However, in a Jan. 28 letter, Maves states "the number of AERs associated with dietary supplements containing ephedrine alkaloids is alarming"...
You may also be interested in...
Acetaminophen resolution
Group also resolves to support legislation to "require, on a national level, enhanced package warning labels on acetaminophen-containing products warning patients that liver failure can result from taking the product in combination with even moderate amounts of alcohol or from taking the product in dosages greater than advised in instructions." AMA also reiterated its call to ban sale of ephedra supplements in the U.S. (1"The Tan Sheet" Feb. 18, 2002, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.